• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin/metformin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nalmefene - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teduglutide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (Fingolimod)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa]
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Spinal surgery for chronic low back pain: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Centralisation of bariatric surgery: policy implications
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Stem cell transplantation for biologic-resistant Crohn's disease
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Remote presence robots in telemedicine
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ablative techniques for the treatment of localised prostate cancer
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Theralite for treatment of renal failure in patients with multiple myeloma
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Drug-eluting stents with CD34 antibodies for the treatment of coronary artery disease
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Online programs for weight loss
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Sutureless aortic valve replacement in patients with severe aortic valve stenosis
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Balloon sinuplasty for chronic rhinosinusitus
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Implantable carotid sinus baroreflex device for treatment of drug resistant hypertension
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Basic fibroblast growth factor (b-FGF) for the treatment of tympanic membrane perforation
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) New and emerging orthopaedic technologies in the Australian and New Zealand public health services
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Miethke proSA adjustable gravitational shunt for hydrocephalus
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) HPV OncoTect E6, E7 mRNA assay to guide colposcopy referral in cervical cancer screening
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) SentiMag and Sienna+ for sentinel lymph node localisation in breast cancer
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Neonatal screening for lysosomal storage disorders
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Out of hours emergency coronary angiography and/or coronary angioplasty and stenting
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Final protocol to guide the assessment of magnetic resonance imaging of liver lesions
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Consultation protocol to guide the assessment of foot and ankle services by podiatric surgeons
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Local anaesthetic (LA) nerve blockade for post-surgical analgesia
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD)
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ear, nose and throat services - surgical services for obstructive sleep apnoea
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MBS reviews paediatric services male circumcision services review report
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Gastrointestinal liner ('EndoBarrier') to treat diabetes and obesity
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Single dose stereotactic radiosurgery for benign or malignant intracranial tumours (Gamma Knife)
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ultrasound imaging in the practice of anaesthesia
2014 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2014 National Institute for Health and Care Excellence (NICE) Teriflunomide for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 303
2014 National Institute for Health and Care Excellence (NICE) Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. NICE technology appraisal guidance 304
2014 National Institute for Health and Care Excellence (NICE) Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance 305
2014 National Institute for Health and Care Excellence (NICE) Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. NICE technology appraisal guidance 306
2014 National Institute for Health and Care Excellence (NICE) Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. NICE technology appraisal guidance 307
2014 National Institute for Health and Care Excellence (NICE) Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2014 National Institute for Health and Care Excellence (NICE) Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 310
2014 National Institute for Health and Care Excellence (NICE) Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. NICE technology appraisal guidance 311
2014 National Institute for Health and Care Excellence (NICE) Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 312
2014 National Institute for Health and Care Excellence (NICE) Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. NICE technology appraisal guidance 314
2014 National Institute for Health and Care Excellence (NICE) Canagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 315
2014 National Institute for Health and Care Excellence (NICE) Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 316
2014 National Institute for Health and Care Excellence (NICE) Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. NICE technology appraisal guidance 317
2014 National Institute for Health and Care Excellence (NICE) Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 319
2014 National Institute for Health and Care Excellence (NICE) Dimethyl fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 320
2014 National Institute for Health and Care Excellence (NICE) Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma. NICE technology appraisal guidance 321
2014 National Institute for Health and Care Excellence (NICE) Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality. NICE technology appraisal guidance 322
2014 National Institute for Health and Care Excellence (NICE) Erythropoiesis stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy. NICE technology appraisal guidance 323
2014 National Institute for Health and Care Excellence (NICE) Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block. NICE technology appraisal guidance 324
2014 National Institute for Health and Care Excellence (NICE) Nalmefene for reducing alcohol consumption in people with alcohol dependence. NICE technology appraisal guidance 325
2014 National Institute for Health and Care Excellence (NICE) Imatinib for the adjuvant treatment of gastrointestinal stromal tumours. NICE technology appraisal guidance 326
2014 National Institute for Health and Care Excellence (NICE) Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 327
2014 National Institute for Health and Care Excellence (NICE) Single-incision laparoscopic cholecystectomy. NICE interventional procedures guidance 508
2014 National Institute for Health and Care Excellence (NICE) Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects. NICE interventional procedures guidance 505
2014 National Institute for Health and Care Excellence (NICE) Insertion of an annular disc implant at lumbar discectomy. NICE interventional procedures guidance 506
2014 National Institute for Health and Care Excellence (NICE) Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula. NICE interventional procedures guidance 507
2014 National Institute for Health and Care Excellence (NICE) Combined endoscopic and laparoscopic removal of colonic polyps. NICE interventional procedures guidance 503
2014 National Institute for Health and Care Excellence (NICE) Total prosthetic replacement of the temporomandibular joint. NICE interventional procedures guidance 500
2014 National Institute for Health and Care Excellence (NICE) Minimally invasive video-assisted thyroidectomy. NICE interventional procedures guidance 499
2014 National Institute for Health and Care Excellence (NICE) Minimally invasive video-assisted parathyroidectomy. NICE interventional procedures guidance 501
2014 National Institute for Health and Care Excellence (NICE) Assessing motility of the gastrointestinal tract using a wireless capsule. NICE interventional procedures guidance 502
2014 National Institute for Health and Care Excellence (NICE) Endoscopic radiofrequency ablation for Barrett's oesophagus with low-grade dysplasia or no dysplasia. NICE interventional procedures guidance 496
2014 National Institute for Health and Care Excellence (NICE) Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. NICE interventional procedures guidance 497
2014 National Institute for Health and Care Excellence (NICE) Powered microdebrider turbinoplasty for inferior turbinate hypertrophy. NICE interventional procedures guidance 498
2014 National Institute for Health and Care Excellence (NICE) Endoscopic saphenous vein harvest for coronary artery bypass grafting. NICE interventional procedures guidance 494
2014 National Institute for Health and Care Excellence (NICE) Radiofrequency tissue reduction for turbinate hypertrophy. NICE interventional procedures guidance 495
2014 National Institute for Health and Care Excellence (NICE) Gastroelectrical stimulation for gastroparesis. NICE interventional procedures guidance 489
2014 National Institute for Health and Care Excellence (NICE) Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. NICE interventional procedures guidance 487
2014 National Institute for Health and Care Excellence (NICE) Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. NICE interventional procedures guidance 493
2014 National Institute for Health and Care Excellence (NICE) Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. NICE interventional procedures guidance 482
2014 National Institute for Health and Care Excellence (NICE) Insertion of a magnetic bead band for faecal incontinence. NICE interventional procedures guidance 483
2014 National Institute for Health and Care Excellence (NICE) Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. NICE interventional procedures guidance 484
2014 National Institute for Health and Care Excellence (NICE) Faecal microbiota transplant for recurrent Clostridium difficile infection. NICE interventional procedures guidance 485
2014 National Institute for Health and Care Excellence (NICE) Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. NICE interventional procedures guidance 478